| Literature DB >> 33542718 |
Megen C Wittling1, Shannon R Cahalan1, Eric A Levenson1, Ronald L Rabin1.
Abstract
Type I interferons (IFN-I) were first discovered as an antiviral factor by Isaacs and Lindenmann in 1957, but they are now known to also modulate innate and adaptive immunity and suppress proliferation of cancer cells. While much has been revealed about IFN-I, it remains a mystery as to why there are 16 different IFN-I gene products, including IFNβ, IFNω, and 12 subtypes of IFNα. Here, we discuss shared and unique aspects of these IFN-I in the context of their evolution, expression patterns, and signaling through their shared heterodimeric receptor. We propose that rather than investigating responses to individual IFN-I, these contexts can serve as an alternative approach toward investigating roles for IFNα subtypes. Finally, we review uses of IFNα and IFNβ as therapeutic agents to suppress chronic viral infections or to treat multiple sclerosis.Entities:
Keywords: human; interferon-alpha; interferon-beta; interferon-omega; primate; type I interferon
Mesh:
Substances:
Year: 2021 PMID: 33542718 PMCID: PMC7850986 DOI: 10.3389/fimmu.2020.605673
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561